$350 Million is the total value of Paradigm Biocapital Advisors LP's 24 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | New | MIRATI THERAPEUTICS INC | $38,156,000 | – | 260,115 | +100.0% | 10.90% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $29,349,000 | – | 218,158 | +100.0% | 8.38% | – |
| ZNTL | New | ZENTALIS PHARMACEUTICALS INC | $25,254,000 | – | 300,434 | +100.0% | 7.21% | – |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $23,903,000 | – | 1,209,051 | +100.0% | 6.83% | – |
| ARNA | New | ARENA PHARMACEUTICALS INC | $23,400,000 | – | 251,777 | +100.0% | 6.68% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $22,845,000 | – | 780,480 | +100.0% | 6.52% | – |
| ARVN | New | ARVINAS INC | $22,056,000 | – | 268,519 | +100.0% | 6.30% | – |
| LEGN | New | LEGEND BIOTECH CORPsponsored ads | $17,990,000 | – | 385,967 | +100.0% | 5.14% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $16,112,000 | – | 844,005 | +100.0% | 4.60% | – |
| SGEN | New | SEAGEN INC | $15,566,000 | – | 100,687 | +100.0% | 4.44% | – |
| ARGX | New | ARGENX SEsponsored adr | $14,725,000 | – | 42,050 | +100.0% | 4.20% | – |
| ISEE | New | IVERIC BIO INC | $13,637,000 | – | 815,581 | +100.0% | 3.90% | – |
| INSM | New | INSMED INC | $10,742,000 | – | 394,358 | +100.0% | 3.07% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $10,325,000 | – | 474,945 | +100.0% | 2.95% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $9,918,000 | – | 453,091 | +100.0% | 2.83% | – |
| GLPG | New | GALAPAGOS NVspon adr | $9,252,000 | – | 167,824 | +100.0% | 2.64% | – |
| CCCC | New | C4 THERAPEUTICS INC | $8,332,000 | – | 258,746 | +100.0% | 2.38% | – |
| KYMR | New | KYMERA THERAPEUTICS INC | $7,991,000 | – | 125,858 | +100.0% | 2.28% | – |
| VOR | New | VOR BIOPHARMA INC | $7,313,000 | – | 629,342 | +100.0% | 2.09% | – |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $5,646,000 | – | 75,507 | +100.0% | 1.61% | – |
| OYST | New | OYSTER PT PHARMA INC | $5,555,000 | – | 304,238 | +100.0% | 1.59% | – |
| IMCR | New | IMMUNOCORE HLDGS PLCads | $4,597,000 | – | 134,249 | +100.0% | 1.31% | – |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $4,196,000 | – | 839,257 | +100.0% | 1.20% | – |
| GRCL | New | GRACELL BIOTECHNOLOGIES INCsponsored ads | $3,294,000 | – | 545,388 | +100.0% | 0.94% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORP | 8 | Q3 2023 | 10.7% |
| MIRATI THERAPEUTICS INC | 8 | Q3 2023 | 10.9% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 6.8% |
| IMMUNOCORE HLDGS PLC | 8 | Q3 2023 | 5.9% |
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| VOR BIOPHARMA INC | 8 | Q3 2023 | 5.0% |
| INCYTE CORP | 7 | Q3 2023 | 8.6% |
| ARGENX SE | 7 | Q3 2023 | 8.7% |
| UNITED THERAPEUTICS CORP DEL | 7 | Q3 2023 | 7.7% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 2.1% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.